Nasdaq
$1.47▼ 0.34%vs prev close
🔒 Quotes & buy pressure are MAX onlySee plans
Market cap $2.6MShares out 1.8M sh
Chart
Filings & news by date
Hover (PC) or tap (mobile) a candle to see that day only
Filings
4- 9.28After-hours26.09.29 05:43ARSOther#●●●
GRI Bio, Inc.
GRI Bio, Inc. has filed its Annual Report to Security Holders (ARS) for the fiscal year ended December 31, 2025. This report provides comprehensive information regarding the company's financial position and business operations to its shareholders.…more
$1.47-0.34%vs prev closeDetected5m · 30m · 60m · Next dayPLUSView filingShare
- 9.28After-hours26.09.29 05:43DEF 14AOther
GRI Bio, Inc.
GRI Bio will hold its 2026 Annual Meeting of Stockholders on November 4, 2026, to vote on the election of directors, ratification of auditors, and an amendment to the 2018 Equity Incentive Plan. The proposed amendment seeks to increase the number of shares available for issuance by 546,529 and extend the evergreen provision until January 1, 2036. As of the record date of September 22, 2026, there are 2,186,115 shares of common stock outstanding.…more
$1.47-0.34%vs prev closeView filingShare - 9.8Pre-market26.09.08 21:168-KKey event
GRI Bio, Inc.
GRI Bio presented new Phase 2a data for its IPF candidate, GRI-0621, at the European Respiratory Society (ERS) Congress. The 12-week study demonstrated improvements in forced vital capacity (FVC) compared to placebo and confirmed consistent therapeutic signals across nine mechanistic pillars.…more
$1.47-0.34%vs prev closeView filingShare
3 more filings
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report
News
GlobeNewswire- 9.28Pre-market26.09.28 21:40#●●●#●●●
GRI Bio to Present Phase 2a Insights at 10th IPF Summit
GRI Bio executives will present findings from their Phase 2a clinical trial of GRI-0621 for idiopathic pulmonary fibrosis at the 10th IPF Summit. The presentation focuses on immune modulation mechanisms and translational research strategies for future development.…more
$1.47-0.34%vs prev closeDetected5m · 30m · 60m · Next dayPLUS
- 9.8Pre-market26.09.08 21:17
●●●●●●●● ●●●●● ●●●●●●
GRI Bio announced that its Phase 2a study for the IPF treatment GRI-0621 showed improved lung function, supporting plans for a longer-duration study. The company is now moving toward further clinical development based on these preliminary findings.…more
$1.47-0.34%vs prev closeShareBenzinga - 9.8Pre-market26.09.08 21:15
●●●●●●●● ●●●●● ●●●●●●
GRI Bio announced positive Phase 2a clinical data for its IPF candidate GRI-0621, showing improvements in lung function and key biomarkers. These exploratory results require further validation through longer-duration clinical trials.…more
$1.47-0.34%vs prev close
2 more news items
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report